Skip to content

The Value of Sleep Respiratory Monitoring in Cardiovascular Risk Assessment in Patients with Diastolic Heart Failure

The Value of Sleep Respiratory Monitoring in Cardiovascular Risk Assessment in Patients with Diastolic Heart Failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116266
Enrollment
Unknown
Registered
2026-01-07
Start date
2023-04-21
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diastolic Heart Failure (Heart Failure with Preserved Ejection Fraction, HFpEF)

Interventions

Observation group of patients with diastolic heart failure combined with/without sleep apnea:None
Patients with diastolic heart failure without sleep apnea:none

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Sign the informed consent form; 3. No concurrent heart failure with reduced ejection fraction, lung disease, neuromuscular disease, mental illness, etc. 4. Echocardiography is used to rule out hypertrophic cardiomyopathy, valvular heart disease, congenital heart disease, etc.

Exclusion criteria

Exclusion criteria: 1. Reduced ejection fraction, heart failure, lung disease, neuromuscular disease, mental illness, etc. 2. Echocardiography shows hypertrophic cardiomyopathy, valvular heart disease, congenital heart disease, etc

Design outcomes

Primary

MeasureTime frame
Diagnostic concordance and severity classification of Diastolic Heart Failure (Heart Failure with Preserved Ejection Fraction, HFpEF);Association strength between the presence of Sleep Apnea (SA) and the risk of developing Diastolic Heart Failure;Coronary Flow Reserve;

Secondary

MeasureTime frame
Severity of left ventricular diastolic dysfunction;Left ventricular mass index and relative wall thickness;Estimated pulmonary artery systolic pressure;Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels;Coronary artery calcium score as observed on Coronary Computed Tomography Angiography (CCTA);Prevalence and control rate of comorbid cardiovascular risk factors;Incidence of a composite endpoint of Major Adverse Cardiovascular Events (MACE);

Countries

China

Contacts

Public ContactDan Yang

Fuwai Hospital, Chinese Academy of Medical Sciences

yangdan@fuwai.com+86 10 8839 6985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026